📣 Second Pre-Clinical Study on Symetrian™ Published

Pre-Clinical Study on Unigen’s Immune Ingredient Published in Journal of Medicinal Foods

Tacoma, Washington-June 12, 2023: The pre-clinical research on UP360 (Symetrian™), Unigen’s novel immune ingredient, has been recently published in the Journal of Medicinal Foods (J Med Food 2023 May 16. doi: 10.1089/jmf.2022.0136; online abstract available.) Unigen evaluated the UP360 standardized composition in lipopolysaccharide (LPS)-induced sepsis and acute inflammatory lung injury murine models. The peer-reviewed paper submitted by Dr. Mesfin Yimam, DVM, MS, Unigen’s Director of Pre-Clinical Research, was a collaborative effort within the bio-tech company’s scientific team.

UP360 (Symetrian™) is a standardized composition from extracts of Aloe vera, Poria cocos mushroom, and Rosemary officinalis. Study results showed the composition protected against sepsis and mitigated acute lung injury in murine models. Sepsis is a life-threatening organ dysfunction caused by a dysregulated and unbalanced immune response to microbial infection. “Restoring immune homeostasis is considered the primary strategy to manage sepsis,” explained Dr. Yimam. “The mushroom-based composition, Symetrian™, was specially designed to possess diverse bioactives with a balanced immune modulatory activity vital for its immune homeostasis function.”

Natural botanical bioactives, such as polysaccharide and polyphenols, are known for their immune modulation activity. Unigen’s next-generation immune support ingredient UP360 (Symetrian™) is comprised of polysaccharides from Aloe vera, beta-glucans from Poria cocos mushroom and polyphenols from Rosemary officinalis. Unigen developed this novel and patent pending mushroom composition by mining its proprietary technology platform PhytoLogix®.

In the pre-clinical report, prophylactic oral administration of UP360 to murine models of sepsis and acute inflammatory lung injury improved the survival rate by 62.5%; reduced proinflammatory cytokines and chemokine such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, IL-6, and cytokine-induced neutrophil chemoattractant (CINC)-3; mitigated lung damage severity by 37.9%; and minimized pulmonary edema by 37%.

Based on the strength of murine model data, a human clinical trial was conducted by KGK Science Inc. showing positive results of UP360 supplementation in helping mount a robust immune response following influenza vaccination. Results were recently published in Frontiers in Nutrition.

For more information on UP360 (Symetrian™), visit the ingredient page and read Unigen’s current blog post “Reviving the Past: Harnessing Ancient Compounds for Modern Immune Support.”


About Unigen, Inc.

Unigen discovers, develops, and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its ingredients through its PhytoLogix® high-throughput screening approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits. Mechanism of action, safety, and efficacy are documented with extensive preclinical in vitro and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacture, distribution, and marketing of end-products in each of Unigen’s target markets.


Kathy Markham, Marketing Manager
Email: kmarkham@unigen.net